No 10Y consistency score yet for revenue — the year-earlier revenue was zero, negative or too small a base to compare against in 21 of the 40 quarters in the window, leaving 19 comparable quarters; at least 28 are needed.
Valuation vs own 10Y history: P/S 1.0x · 10Y median 12.3x · 4th percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 40
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T21:47:36.405Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Unrounded diluted TTM EPS / FMP quote price × 100. Quote observation: 2026-10-06T21:47:36.405Z. Latest historical point 2025-12-16.
The latest delayed quote for NeuroOne Medical Technologies Corporation (NMTC) stock was $1.13 as of Oct 6, 2026, 4:00 PM EDT, up 1.35% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -79.8% · 3-year avg -40.0%/yr · 5-year avg -46.0%/yr
NeuroOne Medical Technologies Corporation functions as a specialized medical technology enterprise. Its core mission involves the invention and market deployment of sophisticated thin-film electrode systems.
Medical - Devices · Eden Prairie, MN
Next Earnings Date
Dec 15, 2026
70 days away
EPS Estimate
-0.22
Revenue Est.
$2.79M
Last Quarter Results
EPS
$-0.23
vs Estimate
$-0.21
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1NMTC | $9.83M | $1.13 | +1.35% | -79.77% | -46.02% | N/A | N/A |
| 2VBIO | $9.86M | $2.38 | -4.03% | -96.66% | N/A | N/A | vs NMTC |
| 3MTVA | $9.75M | $1.48 | -3.90% | -86.28% | N/A | N/A | vs NMTC |
| 4MSLE | $9.71M | $7.54 | -6.34% | N/A | N/A | N/A | vs NMTC |
| 5MDCX | $10.06M | $0.16 | -4.67% | -93.34% | N/A | N/A | vs NMTC |
| 6SNTI | $10.06M | $0.32 | -6.40% | -78.27% | -67.75% | N/A | vs NMTC |
forward FY estimate
N/A
$1.97M
vs Estimate
$1.97M
Consensus Rating
Based on 3 analysts
Average Price Target
$7.27
+543.1% upside
Low
$5.00
Current
$1.13
High
$8.80
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.26 | $-0.22 | $-0.19 | 3 |
| Quarter ending Dec 2026 | $-0.22 | $-0.17 | $-0.14 | 3 |
| Quarter ending Mar 2027 | $-0.20 | $-0.17 | $-0.15 | 1 |
| Quarter ending Jun 2027 | $-0.21 | $-0.18 | $-0.16 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-0.78 | $-0.74 | $-0.66 | 2 |
| FY 2027 | $-0.67 | $-0.63 | $-0.57 | 2 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $2.58M | $2.79M | $3.16M | 3 |
| Quarter ending Dec 2026 | $3.07M | $3.36M | $3.90M | 3 |
| Quarter ending Mar 2027 | $2.79M | $3.05M | $3.54M | 1 |
| Quarter ending Jun 2027 | $2.79M | $3.05M | $3.54M | 1 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $9.33M | $9.54M | $9.92M | 3 |
| FY 2027 | $11.01M | $13.33M | $14.50M | 3 |
